Allianz Global Investors has raised €1.5bn for the final close of its debut private secondaries debt fund, a huge jump compared to its initial €500m target.
Venture capital major Andreessen Horowitz's Bio + Health unit has launched what is says is a "first-of-its-kind" fund to fuel broader innovation in human health in partnership with Eli Lilly.
A rise in the number of large deals saw global private equity healthcare soar to $115bn across 2024, with the segment "roaring back" according to Bain & Company data.
Mid-market private equity investor Vistria Group has closed its biggest fund to date on $3bn, with eyes on US-based healthcare, knowledge and learning companies and financial services businesses.